Next Article in Journal
Development of a Novel UPLC-MS/MS Method for the Simultaneous Determination of 16 Mycotoxins in Different Tea Categories
Previous Article in Journal
Mycotoxins’ Toxicological Mechanisms Involving Humans, Livestock and Their Associated Health Concerns: A Review
 
 
Article

The Preclinical Evaluation of a Second-Generation Antivenom for Treating Snake Envenoming in India

1
Evolutionary Venomics Lab, Centre for Ecological Sciences, Indian Institute of Science, Bangalore 560012, Karnataka, India
2
Serum Institute of India Pvt. Ltd., 212/2, Hadapsar, Off Soli Poonawalla Road, Pune 411028, Maharashtra, India
*
Author to whom correspondence should be addressed.
Toxins 2022, 14(3), 168; https://doi.org/10.3390/toxins14030168
Received: 8 December 2021 / Revised: 3 January 2022 / Accepted: 6 January 2022 / Published: 24 February 2022
Snake envenoming afflicts the Indian subcontinent with the highest rates of mortality (47,000) and morbidity globally. The only effective treatment for snakebites is the administration of antivenom, which is produced by the hyperimmunisation of equines. Commercial Indian antivenoms, however, have been shown to exhibit a poor preclinical performance in neutralising venom, as a result of inter- and intrapopulation snake venom variation. Additionally, their poor dose effectiveness necessitates the administration of larger volumes of antivenom for treatment, leading to several harmful side effects in snakebite victims, including serum sickness and fatal anaphylaxis. In this study, we employed chromatographic purification to enhance the dose efficacy of commercial Indian antivenoms. The efficacy of this ‘second-generation’ antivenom was comparatively evaluated against six other marketed antivenoms using a number of in vitro and in vivo preclinical assays, which revealed its superior venom recognition capability. Enhanced purity also resulted in significant improvements in dose effectiveness, as the ‘second-generation’ antivenom exhibited a 3 to 4.5 times increased venom neutralisation potential. Furthermore, preclinical assays revealed the increased effectiveness of the ‘second-generation’ antivenom in countering morbid effects inflicted by the ‘big four’ Indian snakes. Thus, we demonstrate the role of simpler purification steps in significantly enhancing the effectiveness of snakebite therapy in regions that are most affected by snakebites. View Full-Text
Keywords: snakebite; antivenom therapy; second-generation antivenom; ‘big four’ snakes snakebite; antivenom therapy; second-generation antivenom; ‘big four’ snakes
Show Figures

Figure 1

MDPI and ACS Style

Attarde, S.; Iyer, A.; Khochare, S.; Shaligram, U.; Vikharankar, M.; Sunagar, K. The Preclinical Evaluation of a Second-Generation Antivenom for Treating Snake Envenoming in India. Toxins 2022, 14, 168. https://doi.org/10.3390/toxins14030168

AMA Style

Attarde S, Iyer A, Khochare S, Shaligram U, Vikharankar M, Sunagar K. The Preclinical Evaluation of a Second-Generation Antivenom for Treating Snake Envenoming in India. Toxins. 2022; 14(3):168. https://doi.org/10.3390/toxins14030168

Chicago/Turabian Style

Attarde, Saurabh, Ashwin Iyer, Suyog Khochare, Umesh Shaligram, Mayur Vikharankar, and Kartik Sunagar. 2022. "The Preclinical Evaluation of a Second-Generation Antivenom for Treating Snake Envenoming in India" Toxins 14, no. 3: 168. https://doi.org/10.3390/toxins14030168

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop